Hybrid PET/CT in Cancer Patients

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

Inclusion Criteria:

• Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
• Patients with newly diagnosed metastatic cancer with unknown primary tumor
• Glucose levels below 150-200
• Patient signed informed consent

Exclusion Criteria:

• Pregnant or lactating women
• Patient unable or not willing to tolerate the test until its completion
• One or more of the inclusion criteria is not fulfilled